Transmembrane TNF-α reverse signaling inhibits lipopolysaccharide-induced proinflammatory cytokine formation in macrophages by inducing TGF-β: Therapeutic implications

Journal of Immunology

Volumn 196, Issue 3, 2016, Pages 1146-1157

  Pallai, Anna ^a   Kiss, Beata ^a   Vereb, Gyorgy ^b   Armaka, Marietta ^c   Kollias, George ^c,d   Szekanecz, Zoltan ^b   Szondy, Zsuzsa ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; CYTOKINE; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL SURFACE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; APOPTOSIS; BIOSYNTHESIS; CONFOCAL MICROSCOPY; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; BLOTTING, WESTERN; CYTOKINES; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; MICROSCOPY, CONFOCAL; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84957662599     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501573     Document Type: Article

References (54)

1. Aggarwal, B. B. 2003. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3: 745-756.
2. Pennica, D., G. E. Nedwin, J. S. Hayflick, P. H. Seeburg, R. Derynck, M. A. Palladino, W. J. Kohr, B. B. Aggarwal, and D. V. Goeddel. 1984. Human tumour necrosis factor: precursor structure, expression and homology to lym-photoxin. Nature 312: 724-729.
3. Kriegler, M., C. Perez, K. DeFay, I. Albert, and S. D. Lu. 1988. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 53: 45-53.
4. Luettig, B., T. Decker, and M. L. Lohmann-Matthes. 1989. Evidence for the existence of two forms of membrane tumor necrosis factor: an integral protein and a molecule attached to its receptor. J. Immunol. 143: 4034-4038.
5. Moss, M. L., S. L. Jin, M. E. Milla, D. M. Bickett, W. Burkhart, H. L. Carter, W. J. Chen, W. C. Clay, J. R. Didsbury, D. Hassler, et al. 1997. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor - A. Nature 385: 733-736.
6. Black, R. A., C. T. Rauch, C. J. Kozlosky, J. J. Peschon, J. L. Slack, M. F. Wolfson, B. J. Castner, K. L. Stocking, P. Reddy, S. Srinivasan, et al. 1997. A metalloproteinase disintegrin that releases tumour-necrosis factor - A from cells. Nature 385: 729-733.
7. Vandenabeele, P., W. Declercq, R. Beyaert, and W. Fiers. 1995. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 5: 392-399.
8. Horiuchi, T., H. Mitoma, S. Harashima, H. Tsukamoto, and T. Shimoda. 2010. Transmembrane TNF - A: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 49: 1215-1228.
9. Eissner, G., W. Kolch, and P. Scheurich. 2004. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev. 15: 353-366.
10. Eissner, G., S. Kirchner, H. Lindner, W. Kolch, P. Janosch, M. Grell, P. Scheurich, R. Andreesen, and E. Holler. 2000. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human mono-cytes and macrophages. J. Immunol. 164: 6193-6198.
11. Kirchner, S., S. Boldt, W. Kolch, S. Haffner, S. Kazak, P. Janosch, E. Holler, R. Andreesen, and G. Eissner. 2004. LPS resistance in monocytic cells caused by reverse signaling through transmembrane TNF (mTNF) is mediated by the MAPK/ERK pathway. J. Leukoc. Biol. 75: 324-331.
12. 2 and PAF. J. Clin. Invest. 101: 890-898.
13. Sandborn, W. J., S. B. Hanauer, S. Katz, M. Safdi, D. G. Wolf, R. D. Baerg, W. J. Tremaine, T. Johnson, N. N. Diehl, and A. R. Zinsmeister. 2001. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121: 1088-1094.
14. Tracey, D., L. Klareskog, E. H. Sasso, J. G. Salfeld, and P. P. Tak. 2008. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117: 244-279.
15. Ramos-Casals, M., P. Brito-Zerón, S. Mun-oz, and M. J. Soto, BIOGEAS STUDY Group. 2008. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 87: 345-364.
16. Löwenberg, M., and G. D'Haens. 2015. Next-generation therapeutics for IBD. Curr. Gastroenterol. Rep. 17: 21.
17. Sandborn, W. J., and S. B. Hanauer. 2002. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am. J. Gastroenterol. 97: 2962-2972.
18. Bartolucci, P., J. Ramanoelina, P. Cohen, A. Mahr, P. Godmer, C. Le Hello, and L. Guillevin. 2002. Efficacy of the anti-TNF - Alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 41: 1126-1132.
19. Yee, A. M., and M. B. Pochapin. 2001. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor - A therapy. Ann. Intern. Med. 135: 27-31.
20. Li, M. O., Y. Y. Wan, S. Sanjabi, A. K. Robertson, and R. A. Flavell. 2006. Transforming growth factor-b regulation of immune responses. Annu. Rev. Immunol. 24: 99-146.
21. Pasparakis, M., L. Alexopoulou, V. Episkopou, and G. Kollias. 1996. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral im-mune response. J. Exp. Med. 184: 1397-1411.
22. Grobelny, D., L. Poncz, and R. E. Galardy. 1992. Inhibition of human skin fi-broblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry 31: 7152-7154.
23. Wysk, M., D. D. Yang, H. T. Lu, R. A. Flavell, and R. J. Davis. 1999. Requirement of mitogen - Activated protein kinase kinase 3 (MKK3) for tumor necrosis factor-induced cytokine expression. Proc. Natl. Acad. Sci. USA 96: 3763-3768.
24. Zhang, Y. E. 2009. Non-Smad pathways in TGF-b signaling. Cell Res. 19: 128-139.
25. Li, Y., S. Batra, A. Sassano, B. Majchrzak, D. E. Levy, M. Gaestel, E. N. Fish, R. J. Davis, and L. C. Platanias. 2005. Activation of mitogen - Activated protein kinase kinase (MKK) 3 and MKK6 by type I interferons. J. Biol. Chem. 280: 10001-10010.
26. Wu, W. Z., H. C. Sun, Y. F. Shen, J. Chen, L. Wang, Z. Y. Tang, G. Iliakis, and K. D. Liu. 2005. Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways. J. Cancer Res. Clin. Oncol. 131: 169-178.
27. Massagué, J. 2012. TGFb signalling in context. Nat. Rev. Mol. Cell Biol. 13: 616-630.
28. Davis, R. J. 2000. Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252.
29. Dong, C., R. J. Davis, and R. A. Flavell. 2002. MAP kinases in the immune response. Annu. Rev. Immunol. 20: 55-72.
30. Wiggin, G. R., A. Soloaga, J. M. Foster, V. Murray-Tait, P. Cohen, and J. S. Arthur. 2002. MSK1 and MSK2 are required for the mitogen - And stress-induced phos-phorylation of CREB and ATF1 in fibroblasts. Mol. Cell. Biol. 22: 2871-2881.
31. Xing, J., D. D. Ginty, and M. E. Greenberg. 1996. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 273: 959-963.
32. Kelly, D., B. Scholtz, D. J. Orten, S. H. Hinrichs, and A. Rizzino. 1995. Regulation of the transforming growth factor-beta 2 gene promoter in embryonal carcinoma cells and their differentiated cells: differential utilization of transcription factors. Mol. Reprod. Dev. 40: 135-145.
33. Liu, G., W. Ding, J. Neiman, and K. M. Mulder. 2006. Requirement of Smad3 and CREB-1 in mediating transforming growth factor-b (TGFb) induction of TGFb3 secretion. J. Biol. Chem. 281: 29479-29490.
34. Roberts, A. B., S. J. Kim, T. Noma, A. B. Glick, R. Lafyatis, R. Lechleider, S. B. Jakowlew, A. Geiser, M. A. O'Reilly, D. Danielpour, and M. B. Sporn. 1991. Multiple forms of TGF-b: distinct promoters and differential expression. Ciba Found. Symp. 157: 7-15, discussion 15-28.
35. Xia, D., H. Srinivas, Y. H. Ahn, G. Sethi, X. Sheng, W. K. Yung, Q. Xia, P. J. Chiao, H. Kim, P. H. Brown, et al. 2007. Mitogen - Activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NFkB-dependent pathway. J. Biol. Chem. 282: 3507-3519.
36. Grell, M., F. M. Becke, H. Wajant, D. N. Männel, and P. Scheurich. 1998. TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur. J. Immunol. 28: 257-263.
37. Hart, S. P., J. A. Ross, K. Ross, C. Haslett, and I. Dransfield. 2000. Molecular characterization of the surface of apoptotic neutrophils: implications for functional downregulation and recognition by phagocytes. Cell Death Differ. 7: 493-503.
38. Weinblatt, M. E., J. M. Kremer, A. D. Bankhurst, K. J. Bulpitt, R. M. Fleischmann, R. I. Fox, C. G. Jackson, M. Lange, and D. J. Burge. 1999. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340: 253-259.
39. Maini, R., E. W. St Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, J. Smolen, P. Emery, G. Harriman, M. Feldmann, and P. Lipsky, ATTRACT Study Group. 1999. Infliximab (chimeric anti-tumour necrosis factor a mono-clonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354: 1932-1939.
40. Zhou, H., H. Jang, R. M. Fleischmann, E. Bouman-Thio, Z. Xu, J. C. Marini, C. Pendley, Q. Jiao, G. Shankar, S. J. Marciniak, et al. 2007. Pharmacokinetics and safety of golimumab, a fully human anti-TNF - A monoclonal antibody, in subjects with rheumatoid arthritis. J. Clin. Pharmacol. 47: 383-396.
41. Shull, M. M., I. Ormsby, A. B. Kier, S. Pawlowski, R. J. Diebold, M. Yin, R. Allen, C. Sidman, G. Proetzel, D. Calvin, et al. 1992. Targeted disruption of the mouse transforming growth factor-b1 gene results in multifocal inflammatory disease. Nature 359: 693-699.
42. Randow, F., U. Syrbe, C. Meisel, D. Krausch, H. Zuckermann, C. Platzer, and H. D. Volk. 1995. Mechanism of endotoxin desensitization: involvement of in-terleukin 10 and transforming growth factor b. J. Exp. Med. 181: 1887-1892.
43. Rossol, M., U. Meusch, M. Pierer, S. Kaltenhauser, H. Hantzschel, S. Hauschildt, and U. Wagner. 2007. Interaction between transmembrane TNF and TNFR1/2 mediates the activation of monocytes by contact with T cells. J. Immunol. 179: 4239-4248.
44. Bjorkbacka, H., K. A. Fitzgerald, F. Huet, X. Li, J. A. Gregory, M. A. Lee, C. M. Ordija, N. E. Dowley, D. T. Golenbock, and M. W. Freeman. 2004. The induction of macrophage gene expression by LPS predominantly utilizes Myd88-independent signaling cascades. Physiol. Genomics 19: 319-330.
45. Xiao, Y. Q., K. Malcolm, G. S. Worthen, S. Gardai, W. P. Schiemann, V. A. Fadok, D. L. Bratton, and P. M. Henson. 2002. Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-b. J. Biol. Chem. 277: 14884-14893.
46. Waetzig, G. H., P. Rosenstiel, S. Nikolaus, D. Seegert, and S. Schreiber. 2003. Differential p38 mitogen - Activated protein kinase target phosphorylation in responders and nonresponders to infliximab. Gastroenterology 125: 633-634, au-thor reply 635-636.
47. Nesbitt, A., G. Fossati, M. Bergin, P. Stephens, S. Stephens, R. Foulkes, D. Brown, M. Robinson, and T. Bourne. 2007. Mechanism of action of certo-lizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor a agents. Inflamm. Bowel Dis. 13: 1323-1332.
48. Kirchner, S., E. Holler, S. Haffner, R. Andreesen, and G. Eissner. 2004. Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine 28: 67-74.
49. Fiocchi, C. 2001. TGF-b/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation. J. Clin. Invest. 108: 523-526.
50. Murakozy, G., K. I. Gaede, B. Ruprecht, O. Gutzeit, M. Schurmann, A. Schnabel, M. Schlaak, W. L. Gross, and J. Muller-Quernheim. 2001. Gene polymorphisms of immunoregulatory cytokines and angiotensin-con verting enzyme in Wegener's granulomatosis. J. Mol. Med. (Berl.) 79: 665-670.
51. Piotrowski, W. J., J. Kiszałkiewicz, D. Pastuszak-Lewandoska, A. Antczak P. Gorski, M. Migdalska-Sek, W. Gorski, K. Czarnecka, E. Nawrot, D. Domanska, and E. Brzezianska-Lasota. 2015. TGF-b and SMADs mRNA expression in pulmonary sarcoidosis. Adv. Exp. Med. Biol. 852: 59-69.
52. Hartman, C, D. Berkowitz, B. Weiss, R. Shaoul, A. Levine, O. E. Adiv, R. Shapira, A. Fradkin, M. Wilschanski, A. Tamir, and R. Shamir. 2008. Nu-tritional supplementation with polymeric diet enriched with transforming growth factor-b2 for children with Crohn's disease. Isr. Med. Assoc. J. 10: 503-507.
53. Griffith, T S., and T A. Ferguson. 2011. Cell death in the maintenance and abrogation of tolerance: the five Ws of dying cells. Immunity 35: 456-466.
54. Park, S. Y., M. Y Jung, H. J. Kim, S. J. Lee, S. Y Kim, B. H. Lee, T. H. Kwon, R. W. Park, and I. S. Kim. 2008. Rapid cell corpse clearance by stabilin-2, a membrane phosphatidylserine receptor. Cell Death Differ. 15: 192-201.